Ignite Creation Date:
2024-05-06 @ 6:56 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05830019
Status:
RECRUITING
Last Update Posted:
2023-04-26
First Post:
2021-11-21
Brief Title:
Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery
Sponsor:
Shanghai Proton and Heavy Ion Center
Organization:
Shanghai Proton and Heavy Ion Center
Study Overview
Official Title:
Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for recurrent pancreatic carcinoma post surgery
Detailed Description:
The carbon dose of 675 Gy equivalent in 15 fractions was delivered to clinical target volume CTV The dose limiting toxicity DLT was defined as CTCAE grade 3 or higher of non-hematological toxicity G3 The acute and late toxicities overall survival OS progression-free survival PFS local progression-free survival LPFS and distant metastasis-free survival DMFS were the endpoints
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None